Comparison of hybrid clones derived from human breast epithelial cells and three different cancer cell lines regarding in vitro cancer stem/ initiating cell properties.
Breast Neoplasms
/ metabolism
CD24 Antigen
/ metabolism
Cell Fusion
Cell Movement
Epithelial Cells
/ metabolism
Female
Humans
Hyaluronan Receptors
/ metabolism
Hybrid Cells
/ metabolism
Neoplasms
/ metabolism
Neoplastic Stem Cells
/ metabolism
SOX9 Transcription Factor
/ metabolism
Tumor Cells, Cultured
Breast cancer
Cancer stem cells
Cell fusion
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
19 May 2020
19 May 2020
Historique:
received:
26
09
2019
accepted:
12
05
2020
entrez:
21
5
2020
pubmed:
21
5
2020
medline:
5
1
2021
Statut:
epublish
Résumé
Several physiological (fertilization, placentation, wound healing) and pathophysiological processes (infection with enveloped viruses, cancer) depend on cell fusion. In cancer it was postulated that the fusion of cancer cells with normal cells such as macrophages or stem cells may not only give rise to hybrid cells exhibiting novel properties, such as an increased metastatic capacity and drug resistance, but possibly also cancer stem/ initiating cell properties. Hence, hybrid clone cells (M13HS, M13MDA435 and M13MDA231) that were derived from spontaneous fusion events of human M13SV1-EGFP-Neo breast epithelial cells and HS578T-Hyg, MDA-MB-435-Hyg and MDA-MB-231-Hyg cancer cells were investigated regarding potential in vitro cancer stem/ initiating cell properties. CD44/CD24 expression pattern and ALDH1 activity of parental cells and hybrid clones was determined by flow cytometry. A colony formation and mammosphere formation assay was applied to determine the cells' capability to form colonies and mammospheres. Sox9, Slug and Snail expression levels were determined by Western blot analysis. Flow cytometry revealed that all hybrid clone cells were CD44 The fate whether cancer stem/ initiating cells may originate from cell fusion events likely depends on the specific characteristics of the parental cells.
Sections du résumé
BACKGROUND
BACKGROUND
Several physiological (fertilization, placentation, wound healing) and pathophysiological processes (infection with enveloped viruses, cancer) depend on cell fusion. In cancer it was postulated that the fusion of cancer cells with normal cells such as macrophages or stem cells may not only give rise to hybrid cells exhibiting novel properties, such as an increased metastatic capacity and drug resistance, but possibly also cancer stem/ initiating cell properties. Hence, hybrid clone cells (M13HS, M13MDA435 and M13MDA231) that were derived from spontaneous fusion events of human M13SV1-EGFP-Neo breast epithelial cells and HS578T-Hyg, MDA-MB-435-Hyg and MDA-MB-231-Hyg cancer cells were investigated regarding potential in vitro cancer stem/ initiating cell properties.
METHODS
METHODS
CD44/CD24 expression pattern and ALDH1 activity of parental cells and hybrid clones was determined by flow cytometry. A colony formation and mammosphere formation assay was applied to determine the cells' capability to form colonies and mammospheres. Sox9, Slug and Snail expression levels were determined by Western blot analysis.
RESULTS
RESULTS
Flow cytometry revealed that all hybrid clone cells were CD44
CONCLUSION
CONCLUSIONS
The fate whether cancer stem/ initiating cells may originate from cell fusion events likely depends on the specific characteristics of the parental cells.
Identifiants
pubmed: 32430004
doi: 10.1186/s12885-020-06952-9
pii: 10.1186/s12885-020-06952-9
pmc: PMC7236176
doi:
Substances chimiques
CD24 Antigen
0
CD44 protein, human
0
Hyaluronan Receptors
0
SOX9 Transcription Factor
0
SOX9 protein, human
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
446Subventions
Organisme : Fritz-Bender-Stiftung
ID : not applicable
Références
Adv Exp Med Biol. 2011;714:1-3
pubmed: 21506006
Antisense Nucleic Acid Drug Dev. 2000 Oct;10(5):401-8
pubmed: 11079579
Cells. 2019 Feb 07;8(2):
pubmed: 30736482
Int J Cancer. 2008 Apr 1;122(7):1483-95
pubmed: 18059027
PLoS One. 2013 Jun 26;8(6):e66731
pubmed: 23840523
J Cancer. 2017 Sep 12;8(16):3131-3141
pubmed: 29158785
Cancer Cell Int. 2011 Jun 28;11(1):21
pubmed: 21711510
Cell Stem Cell. 2007 Nov;1(5):555-67
pubmed: 18371393
Cell Rep. 2015 Jun 16;11(10):1549-63
pubmed: 26051943
Cancer Res. 2011 Feb 15;71(4):1497-505
pubmed: 21303980
Sci Adv. 2018 Sep 12;4(9):eaat7828
pubmed: 30214939
Int J Legal Med. 2004 Apr;118(2):119-21
pubmed: 14991368
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9385-90
pubmed: 19458257
BMC Cancer. 2015 Oct 24;15:793
pubmed: 26498753
Int J Mol Sci. 2015 Dec 19;16(12):30362-81
pubmed: 26703575
Am J Pathol. 2015 Jul;185(7):2049-60
pubmed: 26066710
Bone Marrow Transplant. 2004 Jul;34(2):183-6
pubmed: 15195072
PLoS One. 2013 Oct 04;8(10):e77281
pubmed: 24124614
Am J Pathol. 2012 Jun;180(6):2504-15
pubmed: 22542847
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Stem Cells. 2011 Jan;29(1):32-45
pubmed: 21280157
Cancer Res. 2006 Aug 15;66(16):8274-9
pubmed: 16912208
Clin Exp Metastasis. 2011 Jan;28(1):75-90
pubmed: 20981475
Radiat Res. 2001 Jan;155(1 Pt 2):201-207
pubmed: 11121235
Cancer Res. 2013 Sep 1;73(17):5360-70
pubmed: 23856249
Bone Marrow Transplant. 2005 May;35(10):1021-4
pubmed: 15778726
Nat Rev Cancer. 2005 Nov;5(11):899-904
pubmed: 16327766
PLoS One. 2015 Aug 12;10(8):e0134320
pubmed: 26267609
Cancer Res. 2003 Mar 1;63(5):1114-21
pubmed: 12615730
J Cell Mol Med. 2009 Aug;13(8B):2236-52
pubmed: 18681906
Med Hypotheses. 2009 Oct;73(4):542-7
pubmed: 19564079
Cell Commun Signal. 2019 Jul 2;17(1):71
pubmed: 31266502
Sci Rep. 2017 Oct 23;7(1):13856
pubmed: 29062075
Clin Exp Metastasis. 2004;21(6):543-52
pubmed: 15679052
Cancer Res. 2009 Feb 15;69(4):1302-13
pubmed: 19190339
BMC Cancer. 2017 Aug 2;17(1):515
pubmed: 28768501
PLoS One. 2010 Apr 21;5(4):e10277
pubmed: 20422001
Stem Cells Dev. 2015 Nov 1;24(21):2467-78
pubmed: 26192559
Breast Cancer Res. 2008;10(2):R25
pubmed: 18366788
Cell Commun Signal. 2012 Apr 09;10(1):10
pubmed: 22487193
J Cell Biochem. 1988 Feb;36(2):129-36
pubmed: 3356752
Breast Cancer Res. 2008;10(1):R10
pubmed: 18241344
Breast Cancer Res Treat. 2007 Jul;104(1):13-9
pubmed: 17004106
J Clin Pathol. 2011 Nov;64(11):937-46
pubmed: 21680574
PLoS One. 2017 Feb 1;12(2):e0168581
pubmed: 28146572
Cell. 2012 Mar 2;148(5):1015-28
pubmed: 22385965
Cancer Res. 2004 May 15;64(10):3479-85
pubmed: 15150101
Oncogene. 2019 Aug;38(33):6083-6094
pubmed: 31270395
Oncotarget. 2016 Mar 8;7(10):11018-32
pubmed: 26783961
BMC Cancer. 2016 Feb 04;16:56
pubmed: 26846780
Nature. 2015 Sep 10;525(7568):256-60
pubmed: 26331542
J Cancer Res Clin Oncol. 2012 Oct;138(10):1651-8
pubmed: 22622656
Cancer Cell. 2003 May;3(5):445-8
pubmed: 12781362
J Cell Physiol. 2019 Apr;234(4):3570-3582
pubmed: 30417342
Cell Commun Signal. 2018 Apr 10;16(1):14
pubmed: 29636110